The Key Characteristics of Carcinogens: Relationship to the Hallmarks of Cancer, Relevant Biomarkers, and Assays to Measure Them
- PMID: 32152214
- PMCID: PMC7483401
- DOI: 10.1158/1055-9965.EPI-19-1346
The Key Characteristics of Carcinogens: Relationship to the Hallmarks of Cancer, Relevant Biomarkers, and Assays to Measure Them
Abstract
The key characteristics (KC) of human carcinogens provide a uniform approach to evaluating mechanistic evidence in cancer hazard identification. Refinements to the approach were requested by organizations and individuals applying the KCs. We assembled an expert committee with knowledge of carcinogenesis and experience in applying the KCs in cancer hazard identification. We leveraged this expertise and examined the literature to more clearly describe each KC, identify current and emerging assays and in vivo biomarkers that can be used to measure them, and make recommendations for future assay development. We found that the KCs are clearly distinct from the Hallmarks of Cancer, that interrelationships among the KCs can be leveraged to strengthen the KC approach (and an understanding of environmental carcinogenesis), and that the KC approach is applicable to the systematic evaluation of a broad range of potential cancer hazards in vivo and in vitro We identified gaps in coverage of the KCs by current assays. Future efforts should expand the breadth, specificity, and sensitivity of validated assays and biomarkers that can measure the 10 KCs. Refinement of the KC approach will enhance and accelerate carcinogen identification, a first step in cancer prevention.See all articles in this CEBP Focus section, "Environmental Carcinogenesis: Pathways to Prevention."
©2020 American Association for Cancer Research.
Conflict of interest statement
Conflict of Interest Statement: MTS has received consulting fees from attorneys representing plaintiffs in cases involving exposure to benzene, glyphosate and other chemical agents. DWF has received consulting fees from attorneys in cases involving exposure to asbestos, PCBs, TCE and other chemical agents. SM and HL are employees of Amgen. MF was an employee of Amgen during the initial meetings and is currently an employee of Expansion Therapeutics. The other authors declare no competing interests. The views expressed in this publication are those of the authors and do not necessarily represent the decisions, policy or views of their respective institutions. Reference to commercial products or services does not constitute endorsement.
Figures
References
-
- Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100(1):57–70. - PubMed
